Merck, Pfizer And Syndax Collaborate To Evaluate Avelumab With Entinostat

(RTTNews) - Merck KGaA, Pfizer and Syndax Pharmaceuticals, Inc. announced they have entered into a collaboration agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax's entinostat, an investigational oral small molecule that targets immune regulatory cells, in patients with heavily pre-treated, recurrent ovarian cancer.

Avelumab is currently under clinical investigation across a broad range of tumor types by the alliance between Merck KGaA and Pfizer. The announced collaboration is an exclusive agreement between the alliance and Syndax to study the combination of these two investigational agents in ovarian cancer.